1. Pink Sheet
  2. >>Advanced Technologies

Pharma Warming Up To Benefits Of Australia’s Teletrials Initiative

 
• By Vibha Sharma

The Australian teletrials program has surpassed expectations at its mid-way point and is being used by drug and device sponsors looking to enhance trial participant recruitment and retention by enabling access to rural, regional and remote areas.

Clinic, tablet and hands of doctor with patient for consulting, medical service and help in hospital. Healthcare, telehealth and people on digital tech for diagnosis, online results and insurance
Teletrials Use Telecommunications Technology To Allow Primary Sites To Work With Satellite Sites Thousands Of Kilometers Away • Source: Shutterstock

An Australian initiative that uses digital telecommunications to improve access to clinical trials in rural, regional and remote areas and deliver a more diverse pool of study participants for drug and medical device studies in a range of therapeutic areas is making headway.

Key Takeaways

  • The Australian Teletrials Program (ATP) is making good progress in setting up infrastructure needed to enable studies that make use of digital telecommunications to connect regional and rural clinical trial site clusters.

  • Teletrials are a subset of decentralized clinical trials and involve developing trial sites closer to the patient’s home, which can improve access and availability of health services closer to where people live.

  • As teletrials can enhance trial participant recruitment and retention by enabling access to rural, regional and remote areas, the program has drawn the interest of several companies, including Eli Lilly, Novo Nordisk and Sanofi.

  • The ATP covers a five year period (2021-2026) and is supported by a infrastructure-enabling grant of AUD 75.2m ($50.6 m)

The government-funded Australian Teletrials Program (ATP) has conducted over 45 studies at its halfway mark, surpassing expectations, according to program director Kaye Hewson

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Advanced Technologies

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

Potency Assay Issues Delayed US FDA Approval Of Mesoblast’s Ryoncil For Years

 
• By Sue Sutter

The company’s failure to show its potency assays measured attributes directly related to the mesenchymal stromal cell product’s therapeutic effect highlights the importance of a robust CMC program for complex cell therapies.

Mesoblast’s Ryoncil: US FDA Changed Its Mind On Need For A Randomized Trial

 
• By Sue Sutter

Agency staff repeatedly said the BLA based on a single-arm study in 55 patients lacked substantial evidence of effectiveness in steroid-refractory acute graft-versus-host disease and a randomized trial was needed, but changed course “based on additional consideration” after a second CRL.

More from Clinical Trials